Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imaging
Links shared publicly online about this topic.
- 1,133total visits
Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imaging
Repligen Corporation (Nasdaq: RGEN) announced that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from
View full resource at medicalnewstoday.com
Tags: Pancreatic Disease, Drug, Phase 3 Clinical Trial, FDA
Most Recently Shared on May 29, 2010 at 2:34 pm By:
Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imagi... http://mnt.to/f/3Dh4
Also Shared By:
Advertisement
MNT MRI / Ultrasound
@mnt_mri
Repligen Announces FDA And EMA Approval Of Re-analysis Of Images From Phase 3 Trial Of RG1068 For Pancreatic Imaging http://mnt.to/3Dh4
1 year ago...